On June 16, RemeGen (09995.HK) fell 5.06% in regular trading, trading at HKD 68.35/share, with turnover of HKD 129 million. The decline came amid broad-based weakness across Hong Kong-listed innovative drug stocks, as the sector has experienced accelerated selling pressure since early June.

Market concerns over renewed Federal Reserve rate hike expectations, uncertainties surrounding overseas BD (business development) deal prospects, and profit-taking following significant prior gains have combined to trigger persistent capital outflows from the innovative drug sector. Within the Biotechnology sector, Akeso fell 6.04%, 3SBio fell 4.74%, Innovent Biologics fell 1.62%, and BeiGene fell 0.19%, reflecting broadly depressed sector sentiment. Only SKB Bio posted a modest gain of 1.19%.

Notably, just one week earlier on June 9, RemeGen had rallied over 5% after its core product Telitacicept received approval for two new indications. The current pullback reflects broader macro and sector headwinds overriding company-specific positive catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)